PharmaForce Inc., now known as American Regent, is a leading pharmaceutical company with a diverse range of products and services. Their recent acquisition of HBT Labs has expanded their product portfolio and allowed them to enter the oncology market. With this merger, American Regent has significantly enhanced their capabilities in producing complex and highly specialized drugs and delivery systems, enabling them to distribute high-quality medicines efficiently.

One of American Regent's key strategies is the development and delivery of complex injectables that other companies do not provide. By combining forces with HBT Labs, an expert in this niche, American Regent is well-positioned to differentiate themselves in the market. They primarily focus on high-barrier, parenteral generic drugs with complex chemistry and manufacturing processes, including drugs for cancer and CNS disorders.

The merger has also resulted in the addition of a 50,000-square-foot manufacturing facility in Brea, CA, which complements their existing facilities in Ohio and New York, supporting continued innovation. This expansion allows American Regent to effectively manage the development of technically challenging drugs and provides a platform for further innovation, clinical trials, and the commercialization of their products. Furthermore, the merger aligns with American Regent's commitment to expanding their US-based manufacturing capabilities, extending their geographic footprint to the West Coast.

As a united team, they will continue to provide groundbreaking pharmaceutical solutions, ensuring more patients and healthcare providers have access to innovative medicines